On June 18, 2026, CervoMed Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with the investors named therein (the "Investors"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the "Offering"), 2,500,000 shares (the "Shares") of the Company’s common stock, par value $0.001 per share ("Common Stock"), at a purchase price of $4.00 per Share, for aggregate gross proceeds of $10.0 million, before deducting placement agent fees (as described in greater detail below) and related offering expenses. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.